Abarceo Pharma has identified a novel diabetes target located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to functional, preserving beta cell function and allowing patients to produce their own insulin again, naturally.
Dr. Hansen is a former Novonordisk top manager with over 30 years of front-line experience in early stage drug development. He has managed preclinical and clinical R&D of peptide and small molecule diabetes drugs, some of which are on the market today. Dr. Hansen has filled many roles at Novonordisk from project manager to Vice President of R&D. In addition to his role at Abarceo, Dr. Hansen runs a pharmaceutical and biotech consulting firm and works with other biotech and pharmaceutical start-ups.
CSO & Scientific Founder
University of Geneva
Prof. Claes Wollheim is an international authority on beta cells biology and diabetes research. Prof. Wollheim has played a role in advancing diabetes research including 40 years ago changing the view of diabetes from a disease dominated by insulin resistance to one in which beta cell dysfunction is also central.
Associate Professor of Islet Cell Physiology
Prof. Salehi's work is focused on the complex aetiology fo type 2 diabetes (T2D) and the interaction between both genetic and environmental factors including nutritional and metabolic signals. His work addresses the need for T2D therapies to address the root causes and prevent the progressive nature of the disease.